Technical Analysis for ASND - Ascendis Pharma A/S

Grade Last Price % Change Price Change
grade A 73.39 -0.10% -0.07
ASND closed down 0.1 percent on Thursday, January 17, 2019, on 1.13 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ASND trend table...

Date Alert Name Type % Chg
Jan 17 New Uptrend Bullish 0.00%
Jan 17 NR7 Range Contraction 0.00%
Jan 17 Inside Day Range Contraction 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Overbought Stochastic Strength 0.00%
Jan 16 Wide Bands Range Expansion -0.10%
Jan 16 Overbought Stochastic Strength -0.10%
Jan 15 Wide Bands Range Expansion -1.78%
Jan 15 Overbought Stochastic Strength -1.78%
Jan 15 Upper Bollinger Band Touch Strength -1.78%

Older signals for ASND ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Is ASND a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 76.99
52 Week Low 48.0
Average Volume 138,564
200-Day Moving Average 66.0945
50-Day Moving Average 63.5631
20-Day Moving Average 65.6373
10-Day Moving Average 70.725
Average True Range 3.4561
ADX 26.71
+DI 29.3965
-DI 9.9713
Chandelier Exit (Long, 3 ATRs ) 65.4617
Chandelier Exit (Short, 3 ATRs ) 65.0333
Upper Bollinger Band 77.3248
Lower Bollinger Band 53.9498
Percent B (%b) 0.83
BandWidth 35.612373
MACD Line 2.9869
MACD Signal Line 1.9929
MACD Histogram 0.994
Fundamentals Value
Market Cap 2.39 Billion
Num Shares 32.5 Million
EPS -3.61
Price-to-Earnings (P/E) Ratio -20.33
Price-to-Sales 288.07
Price-to-Book 6.90
PEG Ratio -0.32
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 76.32
Resistance 3 (R3) 76.53 75.76 75.83
Resistance 2 (R2) 75.76 75.02 75.66 75.66
Resistance 1 (R1) 74.58 74.56 75.17 74.37 75.50
Pivot Point 73.81 73.81 74.11 73.71 73.81
Support 1 (S1) 72.63 73.07 73.22 72.42 71.28
Support 2 (S2) 71.86 72.61 71.76 71.12
Support 3 (S3) 70.68 71.86 70.95
Support 4 (S4) 70.47